Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors

被引:10
|
作者
Chen, Xiujin [1 ]
Li, Peng [1 ]
Tian, Bin [1 ]
Kang, Xin [1 ]
机构
[1] Xi An Jiao Tong Univ, Honghui Hosp, Dept Orthoped, Xian, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
CAR-T; serious adverse events; lymphoma; leukemia; multiple myeloma; solid tumor; CRS; ICANS; CYTOKINE-RELEASE SYNDROME; ACUTE LYMPHOBLASTIC-LEUKEMIA; CARDIOVASCULAR EVENTS; THERAPY; MANAGEMENT; IMMUNOTHERAPY; REMISSIONS; LYMPHOMA; ADULTS; NEUROTOXICITY;
D O I
10.3389/fimmu.2022.1079181
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chimeric antigen receptor T (CAR-T) cells technology has been successfully used in the treatment of B cell-derived hematological tumors and multiple myeloma. CAR-T cells are also being studied in a variety of solid tumors. Current clinical reports on CAR-T cells in the treatment of malignant tumors are abundant. The tumor-killing activity of CAR-T cells and the unique adverse effects of CAR-T cells have been confirmed by many studies. There is evidence that serious adverse events can be life-threatening. CAR-T cells therapy is increasingly used in clinical settings, so it is important to pay attention to its serious adverse events. In this review, we summarized the serious adverse events of CAR-T cells in the treatment of malignant tumors by reading literature and searching relevant clinical studies, and discussed the management and treatment of serious adverse events in an effort to provide theoretical support for clinicians who deal with such patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
    Miao, Lele
    Zhang, Zhengchao
    Ren, Zhijian
    Tang, Futian
    Li, Yumin
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [2] Comparative Analysis of Mortality from Serious Adverse Events Associated with CAR-T Therapies
    Cho, Heidi
    Maiti, Kausik
    Lunney, Nancy
    Otasevic, Vladimir
    Learn, Chris
    BLOOD, 2024, 144 : 5102 - 5102
  • [3] CAR-T CELLS AND EXO-CAR T CELLS AS NOVEL TREATMENT FOR PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANT TUMORS
    Navarro, M. Ibanez
    Fernandez, A.
    Garcia-Silva, S.
    Clares-Villa, L.
    Ferreras, C.
    Peinado, H.
    Perez-Martinez, A.
    Fernandez, L.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A24 - A25
  • [4] CAR-T Cells in the Treatment of Nervous System Tumors
    Testa, Ugo
    Castelli, Germana
    Pelosi, Elvira
    CANCERS, 2024, 16 (16)
  • [5] CAR-T cells for solid tumors
    不详
    NATURE BIOTECHNOLOGY, 2023, 41 (05) : 588 - 588
  • [7] Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies
    Zhang, Zheng-Zheng
    Wang, Tian
    Wang, Xiao-Feng
    Zhang, Yu-Qing
    Song, Shu-Xia
    Ma, Cui-Qing
    PHARMACOLOGICAL RESEARCH, 2022, 175
  • [8] CAR-T cells development in solid tumors
    El Ghazzi, Nathan
    Italiano, Antoine
    Bay, Jacques-Olivier
    Douge, Aurore
    BULLETIN DU CANCER, 2023, 110 (01) : 32 - 41
  • [10] CAR-T cell therapy: Advances in digestive system malignant tumors
    Xu, Nan
    Wu, Zhonglin
    Pan, Jun
    Xu, Xiao
    Wei, Qiang
    MOLECULAR THERAPY ONCOLOGY, 2024, 32 (04):